Skip to content
sellWeak cluster of 210b5-1 plan

Anish Patel sold $686k of ELVN

CHIEF OPERATING OFFICER at Enliven Therapeutics, Inc.. 28,367 shares at an average of $24.18, traded Jan 7, 2025, filed Jan 10, 2025.

Warning score
34
Value
$686k
28,367 shares
Holdings after
336,644
-131% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    COO
    +20
  • Trade size
    $686k at market
    +21
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ELVNOct 9, 2026 · close 40.98
Since filing Jan 10, 2025: +88.5%SPY +36.8% · excess +51.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001415889-25-001301, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 7, 2025MOption exercise
Common Stock10b5-1
+10,700$1.12$12k10,700Jan 10, 2025
Jan 7, 2025MOption exercise
Common Stock10b5-1
+2,000$2.48$4,96012,700Jan 10, 2025
Jan 7, 2025MOption exercise
Common Stock10b5-1
+9,000$2.48$22k21,700Jan 10, 2025
Jan 7, 2025SOpen-market sale
Common Stock10b5-1
-20,260$24.15$489k1,440Jan 10, 2025
Jan 7, 2025SOpen-market sale
Common Stock10b5-1
-1,440$24.56$35k0Jan 10, 2025
Jan 7, 2025SOpen-market sale
Common Stockindirect: See footnote10b5-1
-6,577$24.17$159k336,734Jan 10, 2025
Jan 7, 2025SOpen-market sale
Common Stockindirect: See footnote10b5-1
-90$24.60$2,214336,644Jan 10, 2025
Jan 7, 2025MOption exercise
Employee Stock Option (right to buy)derivative10b5-1
-10,700$0.00$067Jan 10, 2025
Jan 7, 2025MOption exercise
Employee Stock Option (right to buy)derivative10b5-1
-2,000$0.00$0827Jan 10, 2025
Jan 7, 2025MOption exercise
Employee Stock Option (right to buy)derivative10b5-1
-9,000$0.00$044,342Jan 10, 2025

Related signals

Other insiders at Enliven Therapeutics, Inc. and this insider’s other filings.

ScoreSideCompanyInsiderValueSharesFiled
6Weaksell 210b5-1ELVN
Enliven Therapeutics, Inc.
Helen Louise Collins
CHIEF MEDICAL OFFICER
$252k5,000
14Weaksell 210b5-1ELVN
Enliven Therapeutics, Inc.
Benjamin Hohl
CHIEF FINANCIAL OFFICER
$303k6,018
15Weaksell 310b5-1ELVN
Enliven Therapeutics, Inc.
Benjamin Hohl
CHIEF FINANCIAL OFFICER
$69k3,250
2Weaksell 310b5-1ELVN
Enliven Therapeutics, Inc.
Benjamin Hohl
CHIEF FINANCIAL OFFICER
$23k1,000
23Weaksell 410b5-1ELVN
Enliven Therapeutics, Inc.
Joseph P Lyssikatos
CHIEF SCIENTIFIC OFFICER
$258k12,500
33Weaksell 410b5-1ELVN
Enliven Therapeutics, Inc.
Samuel Kintz
PRESIDENT AND CEO
$260k12,500
26Weaksell 410b5-1ELVN
Enliven Therapeutics, Inc.
Anish Patel
CHIEF OPERATING OFFICER
$143k6,667
8Weaksell 210b5-1ELVN
Enliven Therapeutics, Inc.
Benjamin Hohl
CHIEF FINANCIAL OFFICER
$66k3,250
19Weaksell 210b5-1ELVN
Enliven Therapeutics, Inc.
Anish Patel
CHIEF OPERATING OFFICER
$146k6,667
0Weaksell 210b5-1ELVN
Enliven Therapeutics, Inc.
Benjamin Hohl
CHIEF FINANCIAL OFFICER
$23k1,000

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Anish Patel sold $686k of ELVN | InsiderTell